Last updated: February 26, 2026
What is ISOVUE-M 200?
ISOVUE-M 200 is a contrast agent used in radiographic imaging, specifically serving as an iodine-based contrast medium for angiography, urography, and CT scans. It contains 200 mg/mL of iohexol, a non-ionic, water-soluble iodine compound. The formulation is designed for intravenous injection, offering enhanced imaging clarity with a safety profile suited for a broad patient population.
What is the current excipient composition of ISOVUE-M 200?
The formulation primarily includes the active ingredient iohexol alongside excipients that optimize stability, solubility, and patient safety. Typical excipients consist of:
- Sodium chloride: Maintains isotonicity.
- Potassium iodide: Enhances iodine stability.
- Water for injection: Solvent base.
Additional stabilizers or pH adjusters are not documented explicitly in the original formulation but may vary based on manufacturing.
How does excipient choice influence formulation stability and safety?
Excipients impact multiple aspects:
- Stability: Maintaining iohexol solubility, preventing precipitation.
- Compatibility: Ensuring compatibility with injection equipment and minimizing interactions.
- Biocompatibility: Reducing adverse reactions, particularly allergic responses or nephrotoxicity.
- Shelf-life: Extending product shelf stability via inert, non-reactive excipients.
The current excipient profile prioritizes minimal risk and compatibility with standard sterile processing, with sodium chloride and water being common, well-tolerated excipients.
What are the commercial opportunities tied to excipient innovation?
Innovative use or substitution of excipients in ISOVUE-M 200 opens multiple avenues:
1. Enhanced Safety Profile
Replacing or supplementing current excipients with agents that reduce adverse effects, such as nephrotoxicity, expands clinical use, particularly in vulnerable patients (e.g., those with renal impairment).
2. Formulation Stability
Developing excipients that improve thermostability or extend shelf-life reduces logistic costs, particularly in markets with limited cold chain infrastructure.
3. Reduced Allergic Reactions
Incorporating excipients with lower allergenic potential can increase patient safety and expand market acceptance.
4. Regulatory Differentiation
Introducing novel excipients validated through clinical trials and regulatory approval can differentiate the product, justify premium pricing, or enable use in new indications.
5. Alternative Delivery Forms
Advanced excipients can facilitate formulation into less invasive delivery formats, e.g., pre-filled syringes or ready-to-use solutions, providing convenience and reducing preparation errors.
What are potential strategic steps for excipient-related growth?
- Research on biocompatible excipients: Focus on those proven to reduce adverse reactions.
- Partnerships with excipient suppliers: To develop customized or proprietary excipients tailored for contrast media.
- Investments in stability testing: To validate excipient modifications under diverse storage conditions.
- Regulatory engagement: Early dialogue with authorities on novel excipient approval pathways.
How do market dynamics affect excipient strategy?
The competitive landscape favors formulations with improved safety, stability, and patient compliance. Regulatory pressures to minimize adverse effects and environmental concerns regarding excipient biodegradability influence R&D priorities. Cost pressure entails balancing excipient innovation with material and process costs.
What are key considerations for regulators and manufacturers?
- Safety validation: New excipients require extensive toxicological data.
- Efficacy testing: Ensuring no compromise in imaging quality.
- Manufacturing consistency: Quality control processes must adapt to new excipient sourcing.
- Market acceptance: Education regarding formulation improvements.
Summary table: Excipient innovations and commercial prospects
| Innovation Area |
Benefit |
Potential Market Impact |
Challenges |
| Nephroprotective excipients |
Reduce kidney risk |
Broaden patient eligibility |
Regulatory approval |
| Enhanced stability materials |
Longer shelf life |
Lower logistics costs |
Validation complexity |
| Low-allergen excipients |
Increase safety |
Market differentiation |
Scoping clinical trials |
| Novel delivery excipients |
Facilitate new formats |
Improve commercialization |
Manufacturing scale-up |
Key Takeaways
- ISOVUE-M 200’s current excipient profile is simple, primarily involving sodium chloride and water.
- Excipient innovation can improve safety, stability, and patient compliance.
- Developing biocompatible and stabilizing excipients offers commercial growth potential.
- Regulatory pathways for novel excipients necessitate comprehensive safety and efficacy data.
- Market trends favor formulations optimizing safety profiles and delivery convenience.
FAQs
1. Can excipient modifications improve the safety of ISOVUE-M 200?
Yes. Replacing or supplementing current excipients with agents that mitigate allergic or nephrotoxic reactions can enhance safety.
2. What regulatory hurdles exist for incorporating new excipients?
New excipients require toxicological studies, stability data, and regulatory approval, which can extend development timelines.
3. Are environmentally friendly excipients feasible in contrast media?
Environmental biodegradability can be achieved, but compatibility with the active ingredient and stability must be validated.
4. How does excipient choice influence market differentiation?
Innovative excipients can enable new indications, improve safety, or enhance delivery, offering competitive advantage.
5. What costs are associated with excipient innovation?
Costs include research, development, clinical testing, regulatory submissions, and manufacturing adjustments.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in FDA-Approved Human Drugs and Biologics.
[2] European Medicines Agency. (2021). Note for Guidance on formulation development.
[3] Iohexol manufacturing specs. (2018). [Pharmaceutical formulation documentation].
